Virax Biolabs Group Limited (NASDAQ:VRAX) Sees Large Growth in Short Interest

Virax Biolabs Group Limited (NASDAQ:VRAX) saw a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 266,800 shares, a growth of 467.7% from the May 31st total of 47,000 shares. Based on an average daily trading volume, of 1,390,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 15.4% of the company’s shares are sold short.

Virax Biolabs Group Trading Down 1.7 %

NASDAQ VRAX traded down $0.02 during trading hours on Friday, reaching $1.16. The company had a trading volume of 41,213 shares, compared to its average volume of 4,427,175. The stock has a 50-day moving average of $1.08 and a 200 day moving average of $1.02. Virax Biolabs Group has a 1-year low of $0.60 and a 1-year high of $4.30.

Institutional Trading of Virax Biolabs Group

An institutional investor recently bought a new position in Virax Biolabs Group stock. Armistice Capital LLC purchased a new position in shares of Virax Biolabs Group Limited (NASDAQ:VRAX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 121,999 shares of the company’s stock, valued at approximately $178,000. Armistice Capital LLC owned approximately 7.87% of Virax Biolabs Group as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 8.61% of the company’s stock.

About Virax Biolabs Group

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.